Advertisement

Renoprotective effects of the novel prostaglandin EP4 receptor-selective antagonist ASP7657 in 5/6 nephrectomized chronic kidney disease rats

  • Kazuhiko MizukamiEmail author
  • Hiroyuki Yoshida
  • Eisuke Nozawa
  • Koichi Wada
  • Tohru Ugawa
Original Article
  • 96 Downloads

Abstract

Prostaglandins (PGs) are important lipid mediators of numerous physiologic and pathophysiologic processes in the kidney. PGE2, the most abundant renal PG, plays a major role in renal physiology, including renin release and glomerular hemodynamics. We investigated the renoprotective properties of the novel PGE2 EP4 receptor-selective antagonist ASP7657 in 5/6 nephrectomized rats, a chronic kidney disease (CKD) model. Eight weeks of repeated administration of ASP7657 (0.001–0.1 mg/kg) dose-dependently and significantly reduced urinary protein excretion and attenuated the development of glomerulosclerosis and tubulointerstitial damage, including fibrosis and inflammatory cell infiltration, without affecting blood pressure. Additionally, ASP7657 tended to have beneficial effects on renal function, as indicated by the decrease in plasma creatinine and blood urea nitrogen levels and attenuation of the decline in creatinine clearance (Ccr). The angiotensin II receptor blocker losartan (10 mg/kg) also showed these renoprotective effects while significantly reducing blood pressure. ASP7657 dose-dependently and significantly reduced the EP4 receptor agonist-induced increase in plasma renin activity, as assessed by angiotensin I release in normal rats. Additionally, ASP7657 attenuated hyperfiltration assessed by Ccr without changing the renal blood flow or blood pressure in diabetic rats. These results suggest that ASP7657 suppresses the progression of chronic renal failure by modulating renin release and improving renal hemodynamics, and may therefore be a promising therapeutic option for inhibiting the progression of CKD.

Keywords

Prostaglandin EP4 receptor antagonist Hyperfiltration Renin release Chronic kidney disease 

Notes

Acknowledgments

The authors thank Drs. Akiyoshi Shimaya, Yuichi Tomura, and Atsuo Tahara (Astellas Pharma Inc.) for their valuable comments and continuing encouragement.

Author contributions

KM, HY, EN, KW, and TU conceived and designed the research. KM, HY, and TU performed experiments and analyzed the data. EN contributed to the synthesis of ASP7657. KM and KW wrote the manuscript. All authors read and approved the manuscript.

Compliance with ethical standards

Animal studies were approved by the Institutional Animal Care and Use Committee of Astellas Pharma Inc., Tsukuba Research Center, which is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International.

Conflict of interest

The authors have no conflict of interest other than being employees of Astellas Pharma Inc.

References

  1. Berl T (2009) Review: renal protection by inhibition of the renin-angiotensin-aldosterone system. J Renin-Angiotensin-Aldosterone Syst 10:1–8CrossRefGoogle Scholar
  2. Fine LG, Norman JT (2008) Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 74:867–872CrossRefGoogle Scholar
  3. Fogo AB (2007) Mechanisms of progression of chronic kidney disease. Pediatr Nephrol 22:2011–2022CrossRefGoogle Scholar
  4. Friis UG, Madsen K, Stubbe J, Hansen PB, Svenningsen P, Bie P, Skøtt O, Jensen BL (2013) Regulation of renin secretion by renal juxtaglomerular cells. Pflugers Arch 465:25–37CrossRefGoogle Scholar
  5. Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW (2012) Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol 21:293–300CrossRefGoogle Scholar
  6. Hodgkins KS, Schnaper HW (2012) Tubulointerstitial injury and the progression of chronic kidney disease. Pediatr Nephrol 27:901–909mCrossRefGoogle Scholar
  7. Jian DY, Chao YW, Ting CH, Huang SW, Chang CF, Juan CC, Chen JY (2013) Losartan ameliorates renal injury, hypertension, and adipocytokine imbalance in 5/6 nephrectomized rats. Eur J Pharmacol 709:85–92CrossRefGoogle Scholar
  8. Kasai K, Sato S, Suzuki K (2001) A novel prostaglandin E receptor subtype agonist, 0N0-4819, attenuates acute experimental liver injury in rats. Hepatol Res 21:252–260CrossRefGoogle Scholar
  9. Kikkawa R, Haneda M, Sakamoto K, Koya D, Shikano T, Nakanishi S, Matsuda Y, Shigeta Y (1993) Antagonist for atrial natriuretic peptide receptors ameliorates glomerular hyperfiltration in diabetic rats. Biochem Biophys Res Commun 193:700–705CrossRefGoogle Scholar
  10. Kliem V, Johnson RJ, Alpers CE, Yoshimura A, Couser WG, Koch KM, Floege J (1996) Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int 49:666–678CrossRefGoogle Scholar
  11. Kondo M, Tahara A, Hayashi K, Abe M, Inami H, Ishikawa T, Ito H, Tomura Y (2014) Renoprotective effects of novel interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 through anti-inflammatory action in 5/6 nephrectomized rats. Naunyn Schmiedeberg's Arch Pharmacol 387:909–919CrossRefGoogle Scholar
  12. Lambers Heerspink HJ, de Zeeuw D (2013) Novel drugs and intervention strategies for the treatment of chronic kidney disease. Br J Clin Pharmacol 76:536–550Google Scholar
  13. Lopez-Novoa JM, Martinez-Salgado C, Rodriguez-Pena AB, Lopez-Hernandez FJ (2010) Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives. Pharmacol Ther 128:61–81CrossRefGoogle Scholar
  14. Macconi D (2010) Targeting the renin angiotensin system for remission/regression of chronic kidney disease. Histol Histopathol 25:655–668Google Scholar
  15. Mizukami K, Kamada H, Yoshida H, Ishii I, Nozawa E, Wada K, Ugawa T (2018) Pharmacological properties of ASP7657, a novel, potent and selective prostaglandin EP4 receptor antagonist. Naunyn Schmiedeberg's Arch Pharmacol 391:1319–1326CrossRefGoogle Scholar
  16. Mohamed R, Jayakumar C, Ramesh G (2013) Chronic administration of EP4-selective agonist exacerbates albuminuria and fibrosis of the kidney in streptozotocin-induced diabetic mice through IL-6. Lab Investig 93:933–945CrossRefGoogle Scholar
  17. Nangaku M, Fujita T (2008) Activation of the renin-angiotensin system and chronic hypoxia of the kidney. Hypertens Res 31:175–184CrossRefGoogle Scholar
  18. Narumiya S, Sugimoto Y, Ushikubi F (1999) Prostanoid receptors: structures, properties, and functions. Physiol Rev 79:1193–1226CrossRefGoogle Scholar
  19. Nasrallah R, Hassouneh R, Hébert RL (2016) PGE2, kidney disease, and cardiovascular risk: beyond hypertension and diabetes. J Am Soc Nephrol 27:666–676CrossRefGoogle Scholar
  20. Pöschke A, Kern N, Maruyama T, Pavenstädt H, Narumiya S, Jensen BL, Nüsing RM (2012) The PGE2-EP4 receptor is necessary for stimulation of the renin-angiotensin-aldosterone system in response to low dietary salt intake in vivo. Am J Physiol Renal Physiol 503:F1435–F1442CrossRefGoogle Scholar
  21. Purdy KE, Arendshorst WJ (2000) EP1 and EP4 receptors mediate prostaglandin E2 actions in the microcirculation of rat kidney. Am J Physiol Renal Physiol 279:F755–F764CrossRefGoogle Scholar
  22. Ravera M, Re M, Deferrari L, Vettoretti S, Deferrari G (2006) Importance of blood pressure control in chronic kidney disease. J Am Soc Nephrol 17:S98–S103Google Scholar
  23. Schweda F, Klar J, Narumiya S, Nüsing RM, Kurtz A (2004) Stimulation of renin release by prostaglandin E2 is mediated by EP2 and EP4 receptors in mouse kidneys. Am J Physiol Renal Physiol 287:F427–F433CrossRefGoogle Scholar
  24. Stitt-Cavanagh EM, Faour WH, Takami K, Carter A, Vanderhyden B, Guan Y, Schneider A, Breyer MD, Kennedy CR (2010) A maladaptive role for EP4 receptors in podocytes. J Am Soc Nephrol 21:1678–1690CrossRefGoogle Scholar
  25. Sugimoto H, Shikata K, Matsuda M, Kushiro M, Hayashi Y, Hiragushi K, Wada J, Makino H (1998) Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 41:1426–1434CrossRefGoogle Scholar
  26. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M (2014) Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol 66:975–987CrossRefGoogle Scholar
  27. Tang L, Loutzenhiser K, Loutzenhiser R (2000) Biphasic actions of prostaglandin E2 on the renal afferent arteriole: role of EP3 and EP4 receptors. Circ Res 86:663–670CrossRefGoogle Scholar
  28. Thieme K, Majumder S, Brijmohan AS, Batchu SN, Bowskill BB, Alghamdi TA, Advani SL, Kabir MG, Liu Y, Advani A (2017) EP4 inhibition attenuates the development of diabetic and non-diabetic experimental kidney disease. Sci Rep 7(3442):3442CrossRefGoogle Scholar
  29. Yokoyama U, Iwatsubo K, Umemura M, Fujita T, Ishikawa Y (2013) The prostanoid EP4 receptor and its signaling pathway. Pharmacol Rev 65:1010–1052CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Drug Discovery ResearchAstellas Pharma Inc.IbarakiJapan

Personalised recommendations